BioStem Technologies, Inc.
BSEM
Sync financial data to generate a health grade for this company.
Analytical Summary
Review the statement evidence below to form a view on BSEM.
6-Year Financial Trajectory
QuarterlyStatement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | Q2 FY2026 Jun 30, 2026 10-Q ↗ | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-Q ↗ |
|---|---|---|---|---|---|---|
| Revenue Growth YoY (%) |
-27.9%
Weak
Weak
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Below avg (-449%)
|
— | — | — | — | — |
| Metric | Q2 FY2026 Jun 30, 2026 10-Q ↗ | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-Q ↗ |
|---|---|---|---|---|---|---|
| Operating Margin (%) (%) |
-106.3%
Weak
Weak
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-809%)
|
— | — |
1.0%
Weak
Weak
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-93%)
|
— | — |
| Effective Tax Rate (%) (%) |
0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— | — |
94.0%
Weak
Weak
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— | — |
| Profit Margin (%) (%) |
-113.6%
Weak
Weak
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-1046%)
|
— | — |
0.1%
Weak
Weak
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-99%)
|
— | — |
| Metric | Q2 FY2026 Jun 30, 2026 10-Q ↗ | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-Q ↗ |
|---|---|---|---|---|---|---|
| Return on Invested Capital (%) |
-30.4%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— | — |
0.0%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— | — |
| Return on Capital (%) (%) |
-17.2%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— | — | — | — | — |
| Return on Common Equity (%) (%) |
-32.5%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-317%)
|
— | — |
0.0%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-100%)
|
— | — |
| Metric | Q2 FY2026 Jun 30, 2026 10-Q ↗ | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-Q ↗ |
|---|---|---|---|---|---|---|
| Debt to Equity (x) |
0.00x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-100%)
|
— |
0.00x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-100%)
|
— | — | — |
| Net Debt (USD) | $-6.96M | — | $-29.55M | — | — | — |
| Debt / EBITDA (x) |
0.00x
Excellent
Excellent
Debt relative to earnings before interest, taxes, depreciation
Optimal:
< 2x
|
— | — | — | — | — |
| Metric | Q2 FY2026 Jun 30, 2026 10-Q ↗ | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-Q ↗ |
|---|---|---|---|---|---|---|
| Working Capital (USD) | $-421.29K | — | $33.62M | — | — | — |
| LT Debt (USD) | $0.00 | — | $0.00 | — | — | — |
| Total Equity (USD) | $27.61M | $31.87M | $39.14M | $47.23M | $46.09M | $40.02M |
| Metric | Q2 FY2026 Jun 30, 2026 10-Q ↗ | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-Q ↗ |
|---|---|---|---|---|---|---|
| Sales/Revenue/Turnover (USD) | $7.90M | — | — | $10.96M | — | — |
| Depreciation Expense (USD) | $35.99K | — | — | $29.87K | — | — |
| Net Income, GAAP (USD) | $-8.97M | — | — | $10.61K | — | — |
Secondary lens
Benchmark Lens
Compare BSEM against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare BSEM against peers after checking the statement evidence.
Compare BSEM with peers
Stack BSEM against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced today